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Abstract Benign familial neonatal convulsions, an autosomal
dominant epilepsy of newborns, are linked to mutations affecting
two six-transmembrane potassium channels, KCNQ2 and
KCNQ3. We isolated four splice variants of KCNQ2 in human
brain. Two forms generate, after transient expression in COS
cells, a potassium-selective current similar to the KCNQ1
current. L-735,821, a benzodiazepine molecule which inhibits
the KCNQ1 channel activity (EC50 = 0.08 WM), also blocks
KCNQ2 currents (EC50 = 1.5 WM). Using in situ hybridization,
KCNQ2 and KCNQ3 have been localized within the central
nervous system, in which they are expressed in the same areas,
mainly in the hippocampus, the neocortex and the cerebellar
cortex. During brain development, KCNQ3 is expressed later
than KCNQ2.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
KCNQ1 (KvLQT1) [1] was the ¢rst characterized member
of a new group of six-transmembrane domain potassium
channels, the KCNQ family. Recently two other channels be-
longing to this family were cloned, KCNQ2 [2] and KCNQ3
[3]. All three KCNQ members are associated with inherited
diseases.
KCNQ1, which, in association with a regulatory protein,
KCNE1 (IsK), produces the cardiac slow delayed recti¢er
(IKs) current, [4,5] is responsible for inherited cardiac long
QT disorders [1,6]. These syndromes are the result of muta-
tions in the KCNQ1 gene which alter the functionality of this
channel [7^9]. KCNQ2 and KCNQ3 are both linked to benign
familial neonatal convulsions (BFNC). BFNC is an autoso-
mal dominant idiopathic epilepsy. Typically, seizures start
within the ¢rst week of life and disappear spontaneously after
several weeks or months. Subsequent child development is
normal. However, 10^15% of patients develop seizures later
in life. Investigations of pedigrees of families a¡ected by
BFNC have revealed that single mutations, deletions or inser-
tions in KCNQ2 or KCNQ3 genes are tightly associated with
this disease [2,3,10]. When expressed in Xenopus oocytes
KCNQ2 produces a K current similar to the KCNQ1 cur-
rents [10,11].
In this study, we describe the cloning of four splice variants
of KCNQ2 from human brain and we analyze the functional
expression and the pharmacological pro¢le of this channel
type. In situ hybridization shows that both KCNQ2 and
KCNQ3 are expressed in the same brain areas.
2. Materials and methods
2.1. Ampli¢cation
Human brain cDNAs were used to amplify KCNQx with the Ad-
vantage GC cDNA polymerase kit (Clontech). Ampli¢cations were
performed with the following pro¢le: 94‡C, 1 min, 65‡C, 1 min,
and 68‡C, 4 min, 35 cycles. The primers used for KCNQ2 were de-
signed from the clone published by Biervert et al. [10] (GenBank
database accession number Y15065): K2M 5P-CCTCCGAATTCCC-
ACCATGGTGCAGAAGTC-3P, K2T 5P-GTCCACTGGTCTAGA-
GCCGCCTCACTTCCT-3P.
For KCNQ3, primers K3.1 and K3.2 were designed from GenBank
clones, accession numbers R36327 and R49258 respectively: K3.1 5P-
CGAAGACATGATCCCCACCCTGAA-3P, K3.2 5P-TGGGGCCA-
CCACGCACACGCATGC-3P. Insert K3.1-K3.2 encodes the stop co-
don. PCR products were subcloned into pGEMT-easy vector (Prom-
ega) and sequenced. Clones retained for expression were subcloned
into the pSI mammalian expression vector (Promega). The integrity of
the di¡erent pSI-KCNQx was checked by sequencing.
2.2. Electrophysiological measurements in transfected COS cells
COS-7 cells (American Type Culture Collection, Rockville, MD,
USA) were seeded at a density of 20 000 cells per 35 mm diameter
Petri dish 24 h prior to transfection, and transfected using the classical
DEAE-dextran precipitate method with 0.5 Wg or 1 Wg (in the coex-
pression experiments) of pSI-KCNQx per dish. Cells were tested in
electrophysiology 48 h after transfection.
Electrophysiological recordings were carried out at 22 þ 2‡C in the
whole-cell con¢guration of the patch-clamp technique [12]. The intra-
cellular pipette ¢lling solution contained 150 mM KCl, 0.5 mM
MgCl2, 5 mM EGTA and 10 mM HEPES/KOH at pH 7.2 and the
standard extracellular solution contained 150 mM NaCl, 5 mM KCl,
2 mM CaCl2, 1 mM MgCl2 and 10 mM HEPES/NaOH at pH 7.4.
Drug solutions were freshly prepared from stock solutions.
2.3. Northern blots
Northern blots of human tissues were from Clontech. Membranes
were probed in Xpress bu¡er as described by the manufacturer (Clon-
tech). Blots were exposed on Kodak XAR ¢lm for 30^40 days. Probes
used were a 402 bp insert corresponding to amino acids 167^301 of
KCNQ2 which is common to all isoforms, and a 1092 bp fragment
corresponding to the sequence upstream of the stop codon of
KCNQ3. Poly(A) RNAs, isolated from the brains of 3 day old,
1 week old, 1 month old and adult mice, were blotted as described
previously [13] and probed with the human KCNQ2 and KCNQ3
DNA probes used for human Northern blots. For quanti¢cation,
blots were exposed for 18 h with an imaging plate (Fuji) for a photo
imager (Fuji BAS 1500).
2.4. In situ hybridization
Antisense and sense RNA probes were generated from linearized
plasmids containing, respectively, a 706 bp fragment of KCNQ2
cDNA in the 5P-coding sequence (corresponding to amino acids
101^336) and the 1092 bp fragment of KCNQ3 cDNA. Tissue prep-
aration and hybridization were performed as described in [14]. The
hybridization temperature was 50‡C. Specimens were exposed to
Amersham L-max Hyper¢lm for 10^15 days.
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3. Results
3.1. KCNQ2 splice variants
From the known sequence of KCNQ2 [10] we chose two
oligonucleotides, K2M including the start codon and K2T
including the stop codon. Using these oligonucleotides on
human brain cDNAs we ampli¢ed four di¡erent species of
cDNA encoding KCNQ2 variants. The ¢rst one, herein called
K2vL, corresponded to the KCNQ2 sequence published by
Biervert et al. [10]. It contains the sequence that these authors
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Fig. 1. Amino acid sequence of the K2KL form of KCNQ2. Transmembrane domains are boxed in black. The pore domain, P, is boxed in
gray. Particular exons, K, L and AE, are underlined; AE, additional exon described in [10]. The K2vLMP amino acid sequence change due to
the point mutation is indicated by an asterisk. Using the Prosite server with the ppsearch software based on the Mac Pattern program we iden-
ti¢ed N-glycosylation sites (b), and phosphorylation sites of protein kinase A (R), protein kinase C (F), casein kinase II (E) and tyrosine kin-
ase (a).
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called the additional exon, corresponding to amino acids 373^
382 (Fig. 1). Actually this additional exon was present in all
our clones. Two other KCNQ2 forms, K2KL and K2vKvL,
corresponded to splice forms of K2vL. The K2KL form is
characterized by the presence of exon L, corresponding to
amino acids 417^434 (Fig. 1). The K2vKvL form is charac-
terized by the absence of exon K corresponding to amino
acids 310^319 (Fig. 1). The fourth form, K2vLMP, corre-
sponds to a single base deletion at position 2110 and to a
replacement of a G by an A at position 2120 (positions are
given from the cDNA of the K2KL form where the A of the
ATG codon is at position 1). We veri¢ed that this last form
was not due to a mistake of the reverse transcriptase and/or
Taq DNA polymerases by preparing new cDNAs with anoth-
er reverse transcriptase enzyme (AMV RTase instead of
MMuLV RTase) and by amplifying with other Taq DNA
polymerases (from Gibco and Boehringer). We were able in
all cases to detect the K2vLMP form. The point mutation
leads to a change in the open reading frame which lengthens
the C-terminal end of the K2vLMP protein, which comprises
930 amino acids instead of 872 for the K2KL protein.
3.2. Expression of KCNQ2 splice variants in transfected
COS cells
Among the four splice variants only two, K2KL and K2vL,
were able to generate a selective K current after transfection
into COS cells (Fig. 2). Although K2KL and K2vL di¡er in
their primary amino acid sequence (Fig. 1), they share exactly
the same electrophysiological properties (Fig. 2). These two
forms produce an outward K current which is very similar to
the KCNQ1 current [7]. The main biophysical di¡erences are
a slight shift of the activation curve toward negative voltage
values (V0:5 =337.5 þ 1.2 mV, slope factor k = 14.3 þ 0.8 mV,
n = 11 for K2KL and V0:5 =323.6 þ 1.6 mV, slope factor
k = 11.1 þ 0.9 mV, n = 8 for KCNQ1) and a large increase in
the deactivation kinetics (time constant at 340 mV of
141.3 þ 6.8 ms, n = 8 for K2KL and 621.4 þ 27.0 ms, n = 10
for KCNQ1 [7]) (Fig. 2). The non-functional variants,
K2vKvL and K2vLMP, were assayed for their ability to
interfere with the KCNQ2 channel activity. We also tested
the e¡ect of another clone, called HNSPC, which had been
isolated from neuroblastoma cells and which is also a splice
variant of KCNQ2 [15]. None of the non-active forms was
able to modify the current generated by either K2KL or
K2vL channels. The single transmembrane domain regulatory
subunit KCNE1 (IsK) [4,5] had no e¡ect on the expression of
both active forms of KCNQ2 channel expressed in COS cells.
As the KCNQ2 amino acid sequence contains 12 potential
phosphorylation sites for protein kinase A (PKA) and three
potential phosphorylation sites for protein kinase C (PKC)
(Fig. 1), we examined the possibility of a regulation through
these two phosphorylation pathways. Application of either 8-
Cl-AMPc (500 WM), an activator of PKA, or of the phorbol
12-myristate 13-acetate (PMA), an activator of PKC, did not
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Fig. 2. Electrophysiological characterization of K2KL and K2vL currents expressed in transfected COS cells. A: Typical traces of K2KL cur-
rents elicited by depolarizing voltage steps. Currents are activated by 2 s pulses applied in 20 mV from 380 mV to +60 mV. Tail currents elic-
ited upon repolarization to 360 mV (voltage protocol inset) increased progressively with voltage and saturated at +20 mV. B: K2KL and
K2vL currents measured at the end of the test pulses normalized to cell capacitance (current density) and plotted against test potentials. Data
points are mean þ S.E.M., n = 11 cells for K2KL and n = 7 cells for K2vL. C: Voltage dependence of activation determined from peak tail cur-
rents from experiments as in A. Activation curves were determined by ¢tting peak values of tail currents (Itail) versus test potential (Vt) to a
Boltzmann function: Itail = Itailÿmax/(1+exp [(V0:53Vt)/k] where Itailÿmax is the maximum tail current. The voltage at which the current was half
activated (V0:5) and the slope factor (k) calculated from these data were: 337.5 þ 1.2 mV and 14.3 þ 0.8 mV for K2KL (n = 11 cells) and
335.8 þ 1.8 mV and 12.0 þ 0.9 mV for K2vL (n = 7 cells). D: Kinetics of K2KL and K2vL channel activation and deactivation. Activation
time constant (triangle) was assessed by the same voltage protocol as in A. For deactivation (square), the voltage potential was stepped to +40
mV and then stepped back to voltages ranging from 3120 mV to 330 mV in 10 mV increments, where tail current deactivation time constants
were measured. Activation and deactivation were ¢tted with a single exponential. Data points are mean þ S.E.M., n = 7 cells for activation of
both channels, n = 8 and 9 cells for deactivation of K2KL and K2vL, respectively.
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produce variations of the KCNQ2 channel activity (data not
shown).
The pharmacological properties of the KCNQ2 channel
were investigated using two di¡erent strategies. First we tested
molecules which are known to have an epileptogenic action
such as the MCD peptide (a bee venom toxin) and DTXI (a
mamba venom toxin) [16,17]. Both MCD peptide 1 WM and
DTXI 0.1 WM had no e¡ect on the KCNQ2 channel activity
(data not shown). Next we tested compounds which are
known to be potent activators or inhibitors of KCNQ1 chan-
nel activity such as the benzodiazepine derivative L-364,373
(activator) [18], or chromanol 293B [19] and another benzo-
diazepine derivative, L-735,821 (inhibitors). The KCNQ1 in-
hibitor chromanol 293B had no e¡ect on KCNQ2 activity.
The benzodiazepine L-364,373, which activates KCNQ1
even when expressed alone either in Xenopus oocytes [18] or
in COS cells (not shown), is unable to activate the KCNQ2
channel. Interestingly, the inhibitor L-735,821 reversibly
blocks both KCNQ1 and KCNQ2 channel activities with
EC50s of 0.08 WM for KCNQ1 and 1.5 WM for KCNQ2.
3.3. Northern blot analysis
The KCNQ2 distribution was analyzed by Northern blots
on di¡erent human tissues and compared to the KCNQ3 dis-
tribution. KCNQ2 and KCNQ3 are almost exclusively ex-
pressed in the brain where they hybridize three di¡erent spe-
cies of RNA poly(A) corresponding to 9.5 kb, 4.0 kb and 1.8
kb for KCNQ2 and 12.0 kb, 7.0 kb and 4.0 kb for KCNQ3.
KCNQ2 is also expressed as a band at 1.4 kb in testis and
KCNQ3 as a band at 12.0 kb in spleen (data not shown).
3.4. Developmental expression of KCNQ2 in the brain
and comparison with KCNQ3
KCNQ2 is already present 3 days after birth (P3) in the
mouse and its expression is increased by a factor of 2.5 at
1 week after birth. Then the KCNQ2 expression level remains
stable until the adult stage (P90) (Fig. 3A). KCNQ3 is present
in very low amounts at P3 but its expression increases con-
tinuously until the adult stage. This expression is about two-
fold higher at P30 than at P7 (Fig. 3B). At earlier stages
KCNQ2 expression is higher than that of KCNQ3. The ratio
is maximal at P3 because KCNQ3 expression is very low then.
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Fig. 3. Expression in mouse brain of KCNQ2 (A) and of KCNQ3
(B) mRNAs. Each lane contains 4 Wg of poly(A) mRNAs isolated
from brain of 3 day old (P3), 1 week old (P7), 1 month old (P30)
and adult mice (P90). Autoradiograms were exposed for 8 days at
370‡C. Blots were hybridized with a L-actin probe for relative
quanti¢cation. Relative ratios KCNQx signal/L-actin signal are cal-
culated for each lane using the TINA 2.09 program on BAS reader
1500 apparatus (Fuji).
Fig. 4. Localization of KCNQ2 (A^F) and KCNQ3 (G^I) mRNAs in the mouse brain. Photomicrographs of the autoradiograms of mouse co-
ronal sections after in situ hybridization histochemistry with an antisense riboprobe of a 706 bp fragment of KCNQ2 (A^E), the corresponding
sense riboprobe (F) or an antisense riboprobe of a 1092 bp fragment of KCNQ3 (G^I). Abbreviations: AO, anterior olfactory nuclei ; CPu,
caudate putamen; Cx, neocortex; Fr, frontal olfactory cortex; Gr, cerebellar granular layer; Hip, hippocampus; LSD, lateral septal nucleus
(dorsal part); RF, reticular formation; Th, thalamus. Adjacent sections hybridized with corresponding sense probes revealed no signal.
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At P30 and later no signi¢cant di¡erence exists between the
respective expressions of the two mRNAs species.
3.5. Localization of KCNQ2 in mouse brain by in situ
hybridization and comparison with KCNQ3
KCNQ2 is highly expressed in the hippocampus and den-
tate gyrus, neocortex, and in the granular layer of the cere-
bellum. It is also present in the olfactory bulb, caudate puta-
men, and several septal, thalamic and brainstem nuclei (Fig.
4). KCNQ2 and KCNQ3 hybridization signals are largely
overlapping (Fig. 4), although KCNQ2 signals are stronger.
4. Discussion
We have isolated four variants of KCNQ2 from human
adult brain. Two of them, K2KL and K2vL, are capable of
generating a K current when they are expressed in COS cells.
This K current has the same major characteristics as the
KCNQ1 current an essential component of the IKs channel
in the heart [4,5]. The function of exon L is unknown. The
cytoplasmic segment it encodes at the C-terminal end of the
channel bears no putative phosphorylation site; however, it
could play a role in the association with a putative regulatory
protein.
The two other KCNQ2 forms, K2vKvL and K2vLMP, are
unable to produce a K current. This is not surprising for
K2vKvL since the vK deletion occurs at the end of the sixth
transmembrane segment. This deletion will probably dramat-
ically change the integration of the channel protein in the lipid
bilayer. Results obtained with the K2vLMP form have to be
associated with those obtained with HNSPC, another
KCNQ2 splice variant [15]. HNSPC, which corresponds to a
protein with a very short C-terminal tail, is inactive (our re-
sults and [20]). K2vLMP di¡ers from K2KL at amino acid
709. These data indicate that the cytoplasmic C-terminal part
(approximately the last 150 amino acids) of the KCNQ2 pro-
tein is very important for channel activity. It is therefore not
surprising that recently described mouse brain KCNQ2 iso-
forms, which do not match in their C-terminal part with
K2KL, are inactive [20]. The cytoplasmic C-terminal part of
the KCNQ1 channel is also important for its activity. Muta-
tions associated with long QT syndromes are found in this
portion of the structure and lead to inactive mutants which
in addition act as dominant negatives [7^9]. We analyzed the
possibility that K2vKvL, K2vLMP and HNSPC could act as
negative regulators of the K2KL current, and found that these
variants are without e¡ect on K2KL expression in COS cells.
BFNC is an idiopathic epilepsy with seizures occurring in
the ¢rst days of life and is due to mutations in both KCNQ2
and KCNQ3 [2,3,10]. A recent report indicates that KCNQ2
and KCNQ3 interact to give a current V15-fold larger than
the individual currents obtained with either KCNQ2 or
KCNQ3 alone, suggesting a probable interaction between
the two subunits [11]. Such an interaction would explain
why mutations on either KCNQ2 or KCNQ3 genes lead to
the same symptoms. In situ hybridization shows that KCNQ2
is mainly present in the cerebellar cortex, the neocortex and
the hippocampal formation including the dentate gyrus. This
is interesting since these three structures present distinct epi-
leptic seizure susceptibility [21]. KCNQ3 is localized in the
same areas in mouse brain. However, KCNQ2 expression ap-
pears earlier than that of KCNQ3 and rapidly increases dur-
ing the ¢rst week of life. At birth, KCNQ3 is expressed in a
very low amount whereas KCNQ2 is already expressed at a
signi¢cant level. This indicates that di¡erent pro¢les of asso-
ciation of KCNQ2 and KCNQ3 will probably occur during
development. It will be important to know at the protein level,
using speci¢c antibodies, how and where KCNQ2 and
KCNQ3 appear in human brain during development, and
how di¡erences in expression might be related to the age-de-
pendent seizure remission seen in BFNC. This seizure remis-
sion is probably explained by a compensation mechanism for
defects in KCNQ2/KCNQ3 channels by other types of K
channels which appear a few days after birth [13,22,23].
Although KCNQ2 and KCNQ1 belong to the same protein
family, their pharmacological pro¢les are di¡erent except for
their sensitivity to benzodiazepine L-735,821 which blocks
both channels, but is a more potent blocker of the KCNQ1
channel.
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